Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 31

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 31
---
 pursuant to the November 2024 Keystone Purchase Agreement and 12,500,000 shares of Common Stock pursuant to the July 2025 Keystone Purchase Agreement. The shares of our Common Stock that may be issued under the Keystone Purchase Agreements may be sold by us to Keystone at our discretion from time to time from the applicable Keystone Commencement Date until the earliest to occur of (i) the 36-month anniversary of the effective date of the applicable Registration Statement (as defined below), (ii) the date on which Keystone has purchased the Keystone Commitment Amount pursuant to the Keystone Purchase Agreements, and (iii) the date on which, pursuant to or within the meaning of any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit of our creditors (each, a “Termination Event”). We generally have the right to control the timing and amount of any sales of our Common Stock to Keystone under the Keystone Purchase Agreements. Sales of our Common Stock, if any, to Keystone under the Keystone Purchase Agreements will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant to the Keystone Purchase Agreements. Accordingly, we cannot guarantee that we will be able to sell all of the Keystone Commitment Amount or how much in proceeds we may obtain under the Keystone Purchase Agreements. If we cannot sell securities under the Keystone Equity Financing, we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity and cash position. Because the purchase price per share of Common Stock to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the Keystone Purchase Agreements, if any, will fluctuate based on the market prices of our Common Stock at the time we make such election, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to Keystone under the Keystone Purchase Agreements, the purchase price per share that Keystone will pay for shares of Common Stock purchased from us under the Keystone Purchase Agreements, or the aggregate gross proceeds that we will receive from those purchases by Keystone under the Keystone Purchase Agreements. We previously registered an aggregate of 12,618,310 shares of our Common Stock on